Mass exit at Antev Limited as thirty-one shareholders depart cap table

Thirty-one shareholders have exited the cap table of Antev Limited, according to its latest confirmation statement (period ending 1 June 2026). The Weybridge based clinical stage biotech company, founded in 2013, develops Teverelix, a next generation GnRH antagonist for prostate cancer patients and individuals with acute urinary retention.

The largest departures include Chalemenzaii APS, which held 179,704 shares, and Bar None Investments Ltd, which held 152,879 shares. Other exits from the register include Matos Invest APS with 108,191 shares and Alistrathen APS with 66,360 shares.

Further departures include Redwood Foundation APS (52,562 shares), Faerch and Doetre APS (51,930 shares), and Hanton Invest APS (50,321 shares). Jan Mikkelsen Holding APS, also a shareholder in Amilis Ltd, exited its position of 11,022 shares. A group of 16 additional shareholders with smaller holdings also ceased to be members during this period.

The filings show that Mats Invest AB (29,230 shares), TLA Holdings APS (25,392 shares), and LMST Holding APS (24,748 shares) are among those who have left the register. While these 31 entities departed, 23 existing shareholders remain on the cap table following these changes. This widespread exit of investors may signal a recent secondary transaction.